Evidence map›Paper›PMID 28049649›Full record

ArticleJournal of the American Society of Nephrology : JASN2017

Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype.

Samih H Nasr, Surendra Dasari, John R Mills, Jason D Theis, Michael T Zimmermann, Rafael Fonseca, Julie A Vrana, Steven J Lester, Brooke M McLaughlin, Robert Gillespie and 4 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pharmacological treatment for familial amyloid polyneuropathy.The Cochrane database of systematic reviews · 2020
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Samih H NasrDepartments of Laboratory Medicine and Pathology.
Surendra DasariHealth Sciences Research, and.
John R MillsDepartments of Laboratory Medicine and Pathology.
Jason D TheisDepartments of Laboratory Medicine and Pathology.
Michael T ZimmermannHealth Sciences Research, and.
Rafael FonsecaDepartment of Internal Medicine, Mayo Clinic in Arizona, Phoenix, Arizona.
Julie A VranaDepartments of Laboratory Medicine and Pathology.
Steven J LesterDepartment of Internal Medicine, Mayo Clinic in Arizona, Phoenix, Arizona.
Brooke M McLaughlinDepartment of Clinical Genomics, Mayo Clinic in Arizona, Scottsdale, Arizona.
Robert GillespieDepartment of Cardiology, Sharp Rees-Stealy Medical Group, San Diego, California; and.
W Edward HighsmithDepartments of Laboratory Medicine and Pathology.
John J LeeDepartment of Pathology, Sharp Memorial Hospital, San Diego, California.
Angela DispenzieriDepartments of Laboratory Medicine and Pathology.
Paul J KurtinDepartments of Laboratory Medicine and Pathology, Kurtin.Paul@mayo.edu.
Mayo Clinic Hospital · USMayo Clinic · USMayo Clinic in Arizona · USSharp Memorial Hospital · USSharp Rees-Stealy Medical Group · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lysozyme amyloidosis (ALys) is a rare form of hereditary amyloidosis that typically manifests with renal impairment, gastrointestinal (GI) symptoms, and sicca syndrome, whereas cardiac involvement is exceedingly rare and neuropathy has not been reported. Here, we describe a 40-year-old man with renal impairment, cardiac and GI symptoms, and peripheral neuropathy. Renal biopsy specimen analysis revealed amyloidosis with extensive involvement of glomeruli, vessels, and medulla. Amyloid was also detected in the GI tract. Echocardiographic and electrocardiographic findings were consistent with cardiac involvement. Proteomic analysis of Congo red-positive renal and GI amyloid deposits detected abundant lysozyme C protein. DNA sequencing of the lysozyme gene in the patient and his mother detected a heterozygous c.305T>C alteration in exon 3, which causes a leucine to serine substitution at codon 102 (Human Genome Variation Society nomenclature: p.Leu102Ser; legacy designation: L84S). We also detected the mutant peptide in the proband's renal and GI amyloid deposits. PolyPhen analysis predicted that the mutation damages the encoded protein. Molecular dynamics simulations suggested that the pathogenesis of ALys p.Leu102Ser is mediated by shifting the position of the central β-hairpin coordinated with an antiparallel motion of the C-terminal helix, which may alter the native-state structural ensemble of the molecule, leading to aggregation-prone intermediates.

Indexed as

AdultAmyloidosis, FamilialHumansMaleMuramidasePedigreePhenotypeMuramidaseamyloidosishereditary amyloidlysozymemalfolding proteins

Identifiers

PMID28049649
PMCPMC5280032
OpenAlexW2561410186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.